Inhibikase Therapeutics (IKT) Income towards Parent Company (2020 - 2024)
Historic Income towards Parent Company for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' Income towards Parent Company fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 3556.25%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- According to the latest figures from Q4 2024, Inhibikase Therapeutics' Income towards Parent Company is -$12.9 million, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- In the past 5 years, Inhibikase Therapeutics' Income towards Parent Company ranged from a high of -$421869.0 in Q2 2020 and a low of -$12.9 million during Q4 2024
- For the 5-year period, Inhibikase Therapeutics' Income towards Parent Company averaged around -$4.2 million, with its median value being -$4.6 million (2022).
- In the last 5 years, Inhibikase Therapeutics' Income towards Parent Company tumbled by 56674.67% in 2021 and then surged by 1857.13% in 2024.
- Inhibikase Therapeutics' Income towards Parent Company (Quarter) stood at -$1.2 million in 2020, then plummeted by 317.36% to -$5.0 million in 2021, then grew by 14.02% to -$4.3 million in 2022, then fell by 1.58% to -$4.4 million in 2023, then tumbled by 193.6% to -$12.9 million in 2024.
- Its Income towards Parent Company was -$12.9 million in Q4 2024, compared to -$5.8 million in Q3 2024 and -$5.1 million in Q2 2024.